364 related articles for article (PubMed ID: 22931520)
1. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
Bannwarth B
Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
[TBL] [Abstract][Full Text] [Related]
2. Opioid formulations designed to resist/deter abuse.
Raffa RB; Pergolizzi JV
Drugs; 2010 Sep; 70(13):1657-75. PubMed ID: 20731474
[TBL] [Abstract][Full Text] [Related]
3. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
Ruan X
Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
[TBL] [Abstract][Full Text] [Related]
4. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
Schneider JP; Matthews M; Jamison RN
CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
[TBL] [Abstract][Full Text] [Related]
5. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
Raffa RB; Taylor R; Pergolizzi JV
Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
[TBL] [Abstract][Full Text] [Related]
6. Drug Formulation Advances in Extended-Release Medications for Pain Control.
Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD
Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375
[TBL] [Abstract][Full Text] [Related]
7. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
[TBL] [Abstract][Full Text] [Related]
8. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
Badalamenti VC; Buckley JW; Smith ET
J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
[TBL] [Abstract][Full Text] [Related]
9. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
Fanelli A; Sorella MC; Ghisi D
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
[TBL] [Abstract][Full Text] [Related]
10. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
Smith HS
Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
[TBL] [Abstract][Full Text] [Related]
11. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
12. The implications of tamper-resistant formulations for opioid rotation.
Pappagallo M; Sokolowska M
Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
14. Development and impact of prescription opioid abuse deterrent formulation technologies.
Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
[TBL] [Abstract][Full Text] [Related]
15. Technology: Barriers to misuse.
Dolgin E
Nature; 2015 Jun; 522(7557):S60-1. PubMed ID: 26107099
[No Abstract] [Full Text] [Related]
16. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
[TBL] [Abstract][Full Text] [Related]
17. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
Gasior M; Bond M; Malamut R
Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
[TBL] [Abstract][Full Text] [Related]
18. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
[TBL] [Abstract][Full Text] [Related]
19. Abuse-deterrent opioid formulations.
Med Lett Drugs Ther; 2015 Aug; 57(1476):119-21. PubMed ID: 26305522
[No Abstract] [Full Text] [Related]
20. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
Skak N; Elhauge T; Dayno JM; Lindhardt K
J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
